Caladrius Biosciences, Inc. (CLBS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in ...
As Caladrius Biosciences merges with Cend Therapeutics to become Lisata Therapeutics, it’s leaving a coronary artery disease trial by the wayside. The biotech announced plans to shelve, at least for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results